Can Elafibranor completely cure cholangiocarcinoma?

Elafibranor is an activating PPARα/δ (peroxisome proliferator-activated receptor α/δ) oral medication originally used to treat nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). In recent years, researchers have begun to explore its potential application in hepatobiliary system tumors, especially cholangiocarcinoma (biliary epithelial cell carcinoma). However, the current clinical data are still in the early stages and cannot prove that elafibratenol can "completely cure" cholangiocarcinoma.

Cholangiocarcinoma is a tumor with high malignancy, high recurrence rate, and poor prognosis. The current standard treatment is still surgical resection, supplemented by chemotherapy and targeted therapy. Although irafibratenol has a significant role in improving hepatobiliary metabolic pathways, regulating inflammatory factors and reducing liver fibrosis, in the field of cholangiocarcinoma, it is more used as a potential adjuvant treatment drug, which may be used to delay disease progression or improve sensitivity to other treatment modalities.

As of now, there are no authoritative clinical trials showing that elafibratenol monotherapy can significantly prolong the survival time of patients with cholangiocarcinoma, and there is no data showing that it can "cure" this disease. Some ongoing clinical studies are mainly focused on observing the efficacy of its combination with immunotherapy or chemotherapy. Whether it has a definite anti-tumor effect in the future requires a large amount of data to be verified.

In summary, elafibratenol may have a certain auxiliary role in the treatment of cholangiocarcinoma, but it cannot be used as a first-line or radical regimen at present. For patients with cholangiocarcinoma, irafibratenol is not a cure, but may be a drug that improves liver function and cooperates with other treatments. It is recommended that patients follow the advice of professional doctors and develop a comprehensive treatment plan based on individual conditions.

Reference materials:https://www.drugs.com/

xa0